



March 5, 2018

ReNovo, Inc.
% Mr. Robert Packard
Medical Device Academy, Inc.
345 Lincoln Hill Rd.
Shrewsbury, Vermont 05738

Re: K173741

Trade/Device Name: Reprocessed ArthroCare Ablation Wand
Regulation Number: 21 CFR 878.4400
Regulation Name: Electrosurgical Cutting and Coagulation Device and Accessories
Regulatory Class: Class II
Product Code: NUJ
Dated: December 15, 2018
Received: February 16, 2018

Dear Mr. Packard:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820);

and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/>) and CDRH Learn (<http://www.fda.gov/Training/CDRHLearn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<http://www.fda.gov/DICE>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

**Jennifer R.
Stevenson -S3**

For Binita S. Ashar, M.D., M.B.A., F.A.C.S.
Director
Division of Surgical Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)
K173741

Device Name
Reprocessed ArthroCare Ablation Wands

Indications for Use (Describe)

The Reprocessed ArthroCare Ablation Wands are indicated for resection, ablation, and coagulation of soft tissue and hemostasis of blood vessels in arthroscopic and orthopedic procedures.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:






Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

FDA Form 3881 Indications for Use (Continued)

Arthroscopic and Orthopedic Procedures	Joint Specific or All Joints (ankle, elbow, hip, knee, shoulder, wrist)
Ablation and Debridement	
ACL/PCL	Knee
Acromioplasty	Shoulder
Articular Cartilage	All Joints
Bursectomy	All Joints
Chondroplasty	All Joints
Facia	All Joints
Ligament	All Joints
Notchplasty	Knee
Scar Tissue	All Joints
Soft Tissue	All Joints
Subacromial Decompression	Shoulder
Synovectomy	All Joints
Tendon	All Joints
Excision and Resection	
Acetabular Labrum	Hip
Articular Labrum	All Joints
Capsule	All Joints
Capsular Release	Knee
Cartilage Flaps	Knee
Cysts	All Joints
Discoid Meniscus	Knee
Frozen Shoulder Release	Shoulder
Glenoidale Labrum	Shoulder
Lateral Release	Knee
Ligament	All Joints
Loose Bodies	All Joints
Meniscal Cystectomy	Knee
Meniscectomy	Knee
Pit Removal	All Joints
Scar Tissue	All Joints
Soft Tissue	All Joints
Synovial Membrane	All Joints
Tendon	All Joints
Triangular Fibrocartilage (TFCC)	Wrist
Villusectomy	Knee
Coagulation	
ACL/PCL	Knee
Articular Cartilage	All Joints
Carpal Ligaments	Wrist
Glenohumoral Capsule	Shoulder
Ligament	All Joints
Medial Retinaculum	Knee
Rotator Cuff	Shoulder
Tendon	All Joints
Wrist Tendons	Wrist

K173741 Reprocessed ArthroCare Ablation Wands – Device Models Subject to Clearance

OEM Model Number	Description	Shaft Diameter, description	Picture	OEM 510(k)
ASC4251-01	STARVAC	5.5mm tip diameter, 3.5MM SHAFT SIZE, 90° Tip Angle, 1 screen and 4 ball electrodes,		K083306 K082980
ASH4830-01	SUPER MULTIVAC 50 with Integrated Finger Switches (IFS)	3.0mm Tip Diameter, 3.75mm Shaft Diameter, Flat electrode, 50° tip angle		K082323
ASC4830-01	SUPER MULTIVAC 50	3.0mm Tip Diameter, 3.75mm Shaft Diameter, Flat electrode, 50° tip angle		K072865
ASH4250-01	SUPER TURBOVAC 90 with integrated finger switches (IFS)	5.25mm Tip diameter, 3.75 shaft diameter, screen shape electrode, 9050° tip angle		K071963
AS1335-01	TurboVac 90	3.75mm shaft diameter, 90° Tip Angle		K070958
ASC1335-01	TurboVac™ 90 Integrated Cable Wand	3.75mm shaft diameter, 90° Tip Angle		
AS1336-01	TurboVac 90 XL	3.75mm shaft diameter, 90° Tip Angle		
ASC1336-01	TurboVac 90 XL Integrated Cable Wand	3.75mm shaft diameter, 90° Tip Angle		
AS1337-01	TuboVac 90 HP	3.75 shaft diameter,90° Tip Angle		K033584
AS4360-01	TriStar 50	3.0mm shaft diameter, 50° Tip Angle		K032504
ASC4630-01	TriStar 50 Integrated Cable Wand	3.0mm shaft diameter, 50° Tip Angle		K030551
AS4730-01	MultiVac 50 XL	3.0mm shaft diameter, 50° Tip Angle		K020557
ASC4730-01	MultiVac 50 XL Integrated Cable Wand	3.0mm shaft diameter, 50° Tip Angle		K011083

K173741 - 510(k) SUMMARY

This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of 21 CFR §807.92:

I. SUBMITTER

ReNovo, Inc.
 Mark K. Wells
 340 SW Columbia St.
 Bend OR, 97702 USA
 Tel: +1.541.422.8880
 Fax: +1.541.422.8881

II. CONTACT PERSON

Mary Vater, BS
 Medical Device Academy
 345 Lincoln Hill Rd.
 Shrewsbury, VT 05738 USA
 Tel: +1.913.274-9899
 Email: mary@fdaecopy.com

III. DEVICE

Name of Device:	Reprocessed ArthroCare Ablation Wand
Classification Name:	Electrosurgical Cutting and Coagulation Device and Accessories
Regulation:	21 CFR §878.4400
Regulatory Class:	Class II
Product Classification Code:	NUJ

IV. PREDICATE DEVICE

Predicate Manufacturer	Predicate Submission Name	510(k)
ArthroCare Corp.	Modification To Arthrocare Arthrowands	K083306
ArthroCare Corp.	Arthrocare Arthrowands	K082980
ArthroCare Corp.	Arthrocare Arthrowands	K082323
ArthroCare Corp.	Modificaton To: Arthrocare Arthrowands	K072865
ArthroCare Corp.	Modification To: Arthrocare Arthrowands	K071963
ArthroCare Corp.	Modification To Arthrocare Arthrowands	K070958
ArthroCare Corp.	Arthrocare Arthrowands	K052686
ArthroCare Corp.	Arthrocare Arthrowands	K033584
ArthroCare Corp.	ArthroCare System	K032504
ArthroCare Corp.	ArthroCare ArthroWands	K030551
ArthroCare Corp.	ArthroCare ArthroWands	K020557
ArthroCare Corp.	ArthroCare System	K011083

No reference devices were used in this submission.

V. DEVICE DESCRIPTION

Reprocessed ArthroCare Ablation Wands are radiofrequency surgical devices intended for resection, ablation, and coagulation of soft tissue and hemostasis of blood vessels in arthroscopic and

orthopedic procedures. Ablation wands are powered by a radiofrequency generator or controller. The device variations include various diameters, lengths, or electrode configurations. The materials of construction are generally polycarbonate handles, stainless steel shafts, PET insulation, tungsten electrodes, alumina ceramic tips and PVC suction lines. The electrode design contributes to the performance differences across different model devices.

VI. INDICATIONS FOR USE

The Reprocessed ArthroCare Ablation Wands are indicated for resection, ablation, and coagulation of soft tissue and hemostasis of blood vessels in arthroscopic and orthopedic procedures:

Arthroscopic and Orthopedic Procedures	Joint Specific or All Joints (ankle, elbow, hip, knee, shoulder, wrist)
Ablation and Debridement	
ACL/PCL	Knee
Acromioplasty	Shoulder
Articular Cartilage	All Joints
Bursectomy	All Joints
Chondroplasty	All Joints
Facia	All Joints
Ligament	All Joints
Notchplasty	Knee
Scar Tissue	All Joints
Soft Tissue	All Joints
Subacromial Decompression	Shoulder
Synovectomy	All Joints
Tendon	All Joints
Excision and Resection	
Acetabular Labrum	Hip
Articular Labrum	All Joints
Capsule	All Joints
Capsular Release	Knee
Cartilage Flaps	Knee
Cysts	All Joints
Discoid Meniscus	Knee
Frozen Shoulder Release	Shoulder
Glenoidale Labrum	Shoulder
Lateral Release	Knee
Ligament	All Joints
Loose Bodies	All Joints
Meniscal Cystectomy	Knee
Meniscotomy	Knee
Pilca Removal	All Joints
Scar Tissue	All Joints
Soft Tissue	All Joints
Synovial Membrane	All Joints
Tendon	All Joints
Triangular Fibrocarilage (TFCC)	Wrist

Villusectomy	Knee
Coagulation	
ACL/PCL	Knee
Articular Cartilage	All Joints
Carpal Ligaments	Wrist
Glenohumoral Capsule	Shoulder
Ligament	All Joints
Medial Retinaculum	Knee
Rotator Cuff	Shoulder
Tendon	All Joints
Wrist Tendons	Wrist

VII. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE

The fundamental technological characteristics of the subject device are identical to the predicate devices. The subject devices are reprocessed versions of the predicate devices. Validation was done to ensure that the reprocessing activities did not affect the form or function of the device, and that the reprocessed device performs as well as the original, new device.

The following characteristics were compared between the subject device and the predicate device in order to demonstrate substantial equivalence:

- Indications for Use – The indications for use of the subject device is identical to the predicate (OEM) devices’ indications for use other than the device name, and therefore are substantially equivalent. All are indicated for resection, ablation, and coagulation of soft tissue and hemostasis of blood vessels in arthroscopic and orthopedic procedures.
- Materials – The subject devices are identical reprocessed versions of the predicate OEM devices, therefore the subject devices materials are identical to the predicate.
- Design – The predicate and subject devices are identical in design. No design changes are made during reprocessing.
- Energy Source – The predicate and subject devices are both powered by external RF Generators.
- Performance Testing – The subject devices were tested side by side with predicate devices for thermal effects, probe bending, and probe drop performance. The subject device performed equivalent to the predicate.

VIII. PERFORMANCE DATA

The following performance data were provided in support of the substantial equivalence determination.

Performance Testing

- Cleaning
 - Residual Protein and Carbohydrates
 - Visual Inspection
 - Cleaning Performance Qualification

- Functional
 - Thermal Effects Performance Testing
 - Probe Bending Performance Testing
 - Probe Drop Performance Testing
- Sterilization and Packaging
 - EtO Sterilization Testing
 - EtO Residuals Testing
 - Simulated Shipment Testing
- Product Stability
 - Shelf Life Testing 1-year Accelerated Aging
 - Real-Time Shelf Life studies are on-going and are not complete for inclusion in this submission.

Biocompatibility Testing

The following biocompatibility tests were conducted to ensure the safety of the devices:

- Cytotoxicity
- Irritation
- Acute Systemic
- Material Mediated Pyrogenicity
- Sensitization

Electrical Safety and Electromagnetic Compatibility (EMC)

The following electrical safety and EMC tests have been performed:

- IEC 60601-1-2 EMC Testing
- IEC 60601-2-2 Electrical Safety Testing (high frequency equipment/accessories)

Software Verification and Validation Testing

Software Testing is not applicable, because the device does not contain software or firmware.

Mechanical and Acoustic Testing

Mechanical and acoustic performance testing was not required to demonstrate safety and effectiveness of the device.

Animal Study

Animal performance testing was not required to demonstrate safety and effectiveness of the device.

Clinical Studies

Clinical testing was not required to demonstrate the safety and effectiveness of the Reprocessed ArthroCare Ablation Wand. Instead, substantial equivalence is based upon benchtop performance testing.

IX. CONCLUSIONS

Based on a comparison of technological characteristics, indications for use, and performance data, it can be concluded that the proposed Reprocessed ArthroCare Ablation Wand devices are substantially equivalent to the predicate (OEM) devices.